An interventional study of Placebo and Djulis-Buckwheat in Prehypertension and Hypertension Stage 1, sponsored by Taipei Medical University Hospital. Withdrawn. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-22.
Sponsored by Taipei Medical University Hospital · Not applicable, Interventional, and Prevention
The purpose of the trial is to evaluate the effect of Djulis-Buckwheat drink on cardiovascular protection after ingesting for 8 weeks. In addition, the correlation between the supplement and the cardiovascular disease-related gene expression is evaluated. The results will be used for the application of functional products for cardiovascular protection.
Ninety subjects (age 30\~65) with Prehypertension or Hypertension stage 1 will be included and randomly allocated into 3 groups: Placebo, Djulis-Buckwheat and Buckwheat. The subjects will take sample (100 ml/day) for 8 weeks. Blood pressure will be measured on week 0, 1, 2, 4, 6 and 8. The blood biochemical parameters and gene expression analysis will be examined on week 2, 4, 6, 8 and 10 (the follow up).
Exclusion Criteria:
Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
Dietary Supplement: Placebo · Dietary Supplement: Djulis-Buckwheat
Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
Dietary Supplement: Placebo · Dietary Supplement: Buckwheat
Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
Dietary Supplement: Djulis-Buckwheat · Dietary Supplement: Buckwheat
Ingest placebo drink 100ml/day for 8 weeks
Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
Ingest Buckwheat drink 100ml/day for 8 weeks
Change of blood pressure
Time frame: Baseline, 1, 2, 4, 6, and 8 weeks
No study locations are listed for this record.
This study is withdrawn, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Medical University Hospital